KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Ionis Pharmaceuticals (IONS) over the last 16 years, with Sep 2025 value amounting to $41.1 million.

  • Ionis Pharmaceuticals' Net Cash Flow rose 2.13% to $41.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year increase of 119.32%. This contributed to the annual value of -$156.9 million for FY2024, which is 228.16% down from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Net Cash Flow stood at $41.1 million for Q3 2025, which was up 26.45% from $32.5 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Net Cash Flow peaked at $236.3 million during Q4 2021, and registered a low of -$326.5 million during Q1 2022.
  • Over the past 3 years, Ionis Pharmaceuticals' median Net Cash Flow value was $32.5 million (recorded in 2023), while the average stood at $5.5 million.
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Net Cash Flow plummeted by 2,065.00% in 2022, and later skyrocketed by 673.14% in 2023.
  • Ionis Pharmaceuticals' Net Cash Flow (Quarterly) stood at $236.3 million in 2021, then tumbled by 116.53% to -$39.1 million in 2022, then spiked by 219.99% to $46.9 million in 2023, then tumbled by 296.35% to -$92.0 million in 2024, then increased by 2.13% to $41.1 million in 2025.
  • Its Net Cash Flow stands at $41.1 million for Q3 2025, versus $32.5 million for Q2 2025 and $21.9 million for Q1 2025.